These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 24645735)

  • 1. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
    Andoh T; Yoshida T; Kuraishi Y
    Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
    Andoh T; Kuraishi Y
    J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
    Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
    J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
    Wakita H; Ohkuro M; Ishii N; Hishinuma I; Shirato M
    Exp Dermatol; 2015 Mar; 24(3):215-6. PubMed ID: 25431172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
    Furue M; Kadono T; Tsuji G; Nakahara T
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
    Ishii N; Wakita H; Shirato M
    J Dermatol Sci; 2014 Dec; 76(3):263-4. PubMed ID: 25455141
    [No Abstract]   [Full Text] [Related]  

  • 7. The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice.
    Sugimoto M; Arai I; Futaki N; Hashimoto Y; Sakurai T; Honma Y; Nakaike S
    Eur J Pharmacol; 2007 Jun; 564(1-3):196-203. PubMed ID: 17328887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
    Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S;
    J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
    Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H
    J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.
    Arai I; Takaoka A; Hashimoto Y; Honma Y; Koizumi C; Futaki N; Sugimoto M; Takahashi N; Inoue T; Nakanishi Y; Sakurai T; Tanami T; Yagi M; Ono N; Nakaike S
    Eur J Pharmacol; 2007 Feb; 556(1-3):207-14. PubMed ID: 17141215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
    Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
    J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
    Ohba F; Nomoto M; Hojo S; Akama H
    J Dermatolog Treat; 2016; 27(3):241-6. PubMed ID: 26581111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
    Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
    Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the spontaneous scratching behavior by NC/Nga mice: a possible approach to evaluate antipruritics for subjects with atopic dermatitis.
    Takano N; Arai I; Kurachi M
    Eur J Pharmacol; 2003 Jun; 471(3):223-8. PubMed ID: 12826242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
    Soeberdt M; Kilic A; Abels C
    Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis.
    Ko KC; Tominaga M; Kamata Y; Umehara Y; Matsuda H; Takahashi N; Kina K; Ogawa M; Ogawa H; Takamori K
    Acta Derm Venereol; 2016 Jun; 96(5):624-9. PubMed ID: 26671728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone.
    Inagaki N; Shiraishi N; Igeta K; Itoh T; Chikumoto T; Nagao M; Kim JF; Nagai H
    Eur J Pharmacol; 2006 Sep; 546(1-3):189-96. PubMed ID: 16914137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
    Kitahara Y; Hojo S; Nomoto M; Onozuka D; Furue M; Hagihara A
    J Dermatolog Treat; 2019 Aug; 30(5):466-470. PubMed ID: 30265585
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.
    Terakawa M; Fujieda Y; Tomimori Y; Muto T; Tanaka T; Maruoka H; Nagahira K; Ogata A; Nakatsuka T; Fukuda Y
    Eur J Pharmacol; 2008 Dec; 601(1-3):186-91. PubMed ID: 18996112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice.
    Tanizaki H; Kambe N; Nakamura Y; Tanaka A; Matsuda H; Miyachi Y
    Int Arch Allergy Immunol; 2008; 145(4):277-82. PubMed ID: 18004068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.